MedTrace Logo

Controlled Attenuation Parameter (CAP) in Liver Allografts

NCT02798861 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2020-07-31

Study results available
· View outcomes & findings →

Summary

The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze possible associations between CAP/TE and post-liver transplant (LT) clinical outcomes, and evaluate the change in CAP after LT. The study aims to include as many donors as needed to achieve at least 120 transplanted liver allografts.

Conditions

  • Liver Transplant
  • Liver Steatosis
  • Liver Disease
  • Primary Non-function
  • Early Allograft Dysfunction

Interventions

DEVICE

Fibroscan 402/530

Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.

Sponsors & Collaborators

  • Andres Duarte-Rojo

    lead OTHER

Principal Investigators

  • Andres Duarte-Rojo, MD · University of Pittsburgh

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-07
Primary Completion
2019-06-01
Completion
2019-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02798861 on ClinicalTrials.gov